- Quest Diagnostics ( NYSE: DGX ) announced on Wednesday the launch of a new obstetrics laboratory test panel to enable physicians to screen all eligible pregnant people for hepatitis C with other laboratory tests typically ordered during early pregnancy.
- The company developed the new test panel to include HCV antibody testing in response to findings from a Quest Diagnostics Health Trends study published in Obstetrics & Gynecology in June 2022.
- The study found that less than 41% of pregnant people were screened for HCV in 2021, based on Quest Diagnostic's laboratory testing of more than 5 million pregnant patients.
- Obstetric panels are typically performed early in pregnancy and include guideline-recommended tests, such as complete blood count ( CBC ), blood typing, hepatitis B, syphilis, and rubella, to help guide clinical decisions affecting the pregnancy and mother's health.
For further details see:
Quest Diagnostics launches new obstetrics test panel with hepatitis C screening